What is the next step in management of a biliary mass detected on magnetic resonance cholangiopancreatography (MRCP)?

Next Step for Biliary Mass Detected on MRCP

After detecting a biliary mass on MRCP, proceed immediately with CT chest/abdomen/pelvis for complete staging, followed by tissue acquisition via ERCP with brush cytology and endobiliary forceps biopsy, or EUS-guided biopsy depending on mass location and resectability considerations. 1

Immediate Staging Workup

Once MRCP has identified a biliary mass, complete staging must be performed before any intervention:

• CT chest/abdomen/pelvis with multiphasic liver imaging to assess for distant metastases, evaluate hepatic artery and portal vein involvement, and detect lymphadenopathy 1, 2
• Blood tests to assess liver function and screen for underlying liver disease (HBV, HCV, autoimmune conditions) 1
• EUS with fine needle aspiration/biopsy to rule out metastatic lymph nodes if surgical treatment is being considered 2

The 2025 EASL guidelines emphasize that staging should ideally be completed before biliary stent placement to avoid artifacts that complicate interpretation 2.

Tissue Acquisition Strategy

Pathological confirmation via core biopsy is mandatory before any non-surgical treatment 1. The approach depends on mass location and treatment intent:

For Perihilar or Distal Cholangiocarcinoma:

• Primary approach: ERCP with brush cytology PLUS endobiliary forceps biopsy whenever technically feasible 1, 2

  • Brush cytology alone has only ~45% sensitivity 2
  • Adding forceps biopsy increases joint sensitivity to 66% 2
  • This provides adequate tissue for both diagnosis and molecular profiling (NGS) 1

• Alternative/adjunct: Cholangioscopy-directed biopsies if available and initial methods fail 2

  • Increases sensitivity from 61% to 72% (27% incremental yield) 2
  • Particularly useful for extrahepatic lesions 2

Critical Caveat - Avoid Transperitoneal EUS Biopsy If:

Do NOT perform EUS-guided transperitoneal biopsy in potentially resectable tumors or liver transplant candidates due to risk of peritoneal seeding 1, 2. While the absolute risk appears very low, this decision must be made in a multidisciplinary setting 1.

• EUS-FNA/FNB may be considered for:
  • Regional lymph node sampling (if enlarged) 1
  • Unresectable disease where seeding risk is irrelevant 2
  • When ERCP-guided methods are negative/inconclusive AND resection is not planned 1

Molecular Profiling

For advanced disease suitable for systemic treatment, obtain tissue adequate for next-generation sequencing (NGS) 1:

• Priority targets: IDH1, FGFR2 fusions, HER2/ERBB2, BRAF, NTRK fusions 1
• Intrahepatic cholangiocarcinomas are particularly enriched for actionable targets 1
• Liquid biopsy (cell-free circulating DNA) may be considered if tissue is insufficient 1

Algorithmic Approach

1. MRCP identifies biliary mass → Confirm anatomical location (intrahepatic, perihilar, distal, gallbladder)
2. Complete staging → CT chest/abdomen/pelvis + blood tests (BEFORE stenting if possible)
3. Multidisciplinary team review → Assess resectability and determine tissue acquisition strategy
4. Tissue acquisition:
   • If potentially resectable → ERCP with brush cytology + forceps biopsy (avoid transperitoneal EUS)
   • If unresectable/metastatic → Any method including EUS-FNA/FNB acceptable
   • Ensure adequate tissue for NGS in advanced disease
5. EUS for nodal staging if surgical treatment considered
6. Optional: PET-CT may help identify occult metastases or disease recurrence 1

Common Pitfalls

• Stenting before complete staging complicates subsequent imaging interpretation 2
• Relying on brush cytology alone misses >50% of malignancies 2
• Performing transperitoneal EUS biopsy in transplant candidates risks peritoneal seeding 2
• Inadequate tissue sampling prevents molecular profiling needed for targeted therapies 1
• Skipping multidisciplinary review before biopsy decisions in potentially resectable cases 1

The 2023 ESMO and 2025 EASL guidelines provide the most current evidence-based framework for this diagnostic pathway 1, 2.